Literature DB >> 12491507

Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.

Neil M Harris1, William R Anderson, Bashir A Lwaleed, Alan J Cooper, Brian R Birch, Lemke Z Solomon.   

Abstract

BACKGROUND: Anthracyclines have been established as first-line drugs for intravesical use in the treatment of patients with superficial bladder carcinoma, although they result only in a modest reduction in tumor recurrence rates. The essential fatty acid gamma-linolenic acid (GLA) also is an effective cytotoxic agent against superficial bladder carcinoma when it is applied topically. The objective of this study was to assess the efficacy of combined epirubicin and GLA with the purpose of developing a suitable model for modification of existing intravesical regimens.
METHODS: The human urothelial carcinoma cell lines MGH-U1 and RT112 were used in standard cytotoxicity assays and were exposed to meglumine GLA (MeGLA) and epirubicin in two-dimensional concentration matrices. A thiozolyl blue (methyl-thiazoldiphenyl tetrazolium) assay was used to determine residual cell biomass. Drug interaction was quantified by median-effect analysis software (CalcuSyn), and the evaluation of drug uptake utilized fluorescence confocal microscopy (FCM) and flow cytometry.
RESULTS: MeGLA caused a significant enhancement of anthracycline uptake, viewed by FCM, from 92 fluorescence units to 222 fluorescence units (P < 0.001). Flow cytometry confirmed the increased drug uptake and showed that the mean epirubicin content per cell increased from 23 to 57 units and from 8 to 24 units for MGH-U1 and RT112 cells, respectively (99% confidence interval < 0.3). This resulted in improved cytotoxicity, and it was shown that the drugs acted synergistically with all but the highest MeGLA concentrations.
CONCLUSIONS: The efficacy of epirubicin was enhanced significantly when it was used in combination with most concentrations of MeGLA (< 300 microg/mL), and the two agents acted synergistically. There was a corresponding increase in epirubicin uptake by cells under these conditions. At high MeGLA concentrations, however, anthracycline solubility was compromised, and drug synergy was lost. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12491507     DOI: 10.1002/cncr.11055

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  New therapies for non-muscle-invasive bladder cancer.

Authors:  Edmund Chiong; Kesavan Esuvaranathan
Journal:  World J Urol       Date:  2009-09-18       Impact factor: 4.226

2.  Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions.

Authors:  Ephraim P Lansky; Wenguo Jiang; Huanbiao Mo; Lou Bravo; Paul Froom; Weiping Yu; Neil M Harris; Ishak Neeman; Moray J Campbell
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

3.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Authors:  Roman Rouzier; Radhika Rajan; Peter Wagner; Kenneth R Hess; David L Gold; James Stec; Mark Ayers; Jeffrey S Ross; Peter Zhang; Thomas A Buchholz; Henry Kuerer; Marjorie Green; Banu Arun; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.